Case Studies
Demonstrated expertise of Newland Global Group’s (NGG) advisory work
NGG taps its unparalleled internal and external ecosystem of experts, relationships, access, and industry intelligence to ensure that our clients achieve their goals. NGG is committed to crafting precedent-setting deals driven by our clients’ ideas, interests, and opportunities. Our goal is to help our clients achieve their ambitions.
NGG’s specialists amalgamate business acumen and profound sector knowledge with technical know-how and state-of-the-art analytic tools so that clients stay in front of the issues and make the best decisions. We have the workforce and capabilities to execute clients’ decisions – beginning right with the strategy, through seamless execution, to tangible results.
We analyse the current plan and prepare for the future by assisting our clients in seizing prospective opportunities. We are proud to share how we have helped our clients achieve their business-driven goals.
NGG advised Cadila Pharmaceuticals on entering the Australian market
Cadila Pharmaceuticals is a multinational research-based pharmaceutical group in India with more than six decades of experience. Cadila’s integrated operations cover the entire gamut from manufacturing products ranging from API’s-Intermediates, Finished Formulations, OTC-Food Supplements, Biotechnology Products, and Pharmaceutical Machinery. Cadila’s manufacturing facilities are approved by the most stringent international bodies like WHO-GMP, UK-MHRA, USFDA-API, TGA-Australia and AIFA-Italy. The global operations of Cadila are spread across 58 countries including the Americas, Japan, Asia, CIS and Africa.
Cadila engaged NGG to look for opportunities to explore strategic options for the company in generic medicines, supply of Active Pharmaceutical Ingredients (APIs), opportunities to invest in the Australian biotechnology sector and pharmaceutical manufacturing in Australia.
India has a prominent and rapidly growing presence in global pharmaceuticals. It is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, and supplies 50% of global demand for vaccines. India is the source of 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different APIs. India ranks third worldwide for production by volume and 13th by value, thereby accounting for around 10% of world’s production by volume and 1.5% by value.
NGG started by engaging on the opportunity with several pre-qualified potential partners. A thorough market assessment report was conducted by NGG to identify potential opportunities for Cadila. NGG identified three key companies, which were interested in private labelling for generic medicines. Also, five Australian biotech companies were identified, which underwent rigorous assessment for securing investment on their Intellectual Property by Cadila scientists. NGG reviewed and prepared all key materials highlighting Cadila’s historical performance and robust platform to pursue growth opportunities.
NGG also identified an opportunity for Cadila to manufacture in Australia. Cadila’s senior executives were introduced to one of the largest producers of vitamins and nutraceuticals, which was owned and managed by an Australian Private Equity company.